Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment   in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO , May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

SAN DIEGO , April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment   in the second quarter of 2024. Company launches Individual Patient Expanded Access Program (EAP), allowing access to efzofitimod for patients who complete EFZO-FIT™.

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary

  Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT ™ study in pulmonary sarcoidosis. Company initiating program based on blinded EFZO-FIT ™ study investigator and patient participant feedback. SAN DIEGO , Feb.

  Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism. Role of NRP2 in immune system validated by activity of NRP2 blocking antibody in preclinical models. SAN DIEGO , Jan.

Dr. Frederick to advise Company on corporate affairs and commercial strategy for efzofitimod in interstitial lung disease (ILD). SAN DIEGO , Jan. 18, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotechnology company engaged in the discovery

Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models. SAN DIEGO , Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient dosing. Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and

SAN DIEGO , Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.